

## DAFTAR PUSTAKA

- Sotgiu G, Tiberi S, Centis R, D'Ambrosio L, Fuentes Z, Zumla A, et al. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. *Int J Infect Dis*. 2017;56:190–3.
- Kementerian Kesehatan RI. Petunjuk teknis manajemen terpadu pengendalian tuberkulosis resisten obat. 2014.
- World Health Organization. Global tuberculosis report 2018. Geneva. 2018.
- Subdit TB Kemenkes RI. Laporan kasus tb mdr RSUP Persahabatan 2009-2016. e TB manager. 2018.
- Kementerian Kesehatan RI. Peraturan menteri kesehatan republik indonesia nomor 67 tahun 2016 tentang penanggulangan tuberkulosis. 2016. 19-117.
  - WHO. *Global Tuberculosis Report 2011*. Geneva: WHO Press (2011). Available from: [http://whqlibdoc.who.int/publications/2011/9789241564380\\_eng.pdf](http://whqlibdoc.who.int/publications/2011/9789241564380_eng.pdf)
- McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. *J Infect Dis* (2012) **15**:S147–58. doi:10.1093/infdis/jjr860
- Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, O'Grady J, et al. Viewpoint: scientific dogmas, paradoxes and mysteries of latent *Mycobacterium tuberculosis* infection. *Trop Med Int Health* (2011) **16**:79–83. doi:10.1111/j.1365-3156.2010.02665.x
- Whitworth HS, Scott M, Connell DW, Dongés B, Lalvani A. IGRAs – the gate-way to T cell based TB diagnosis. *Methods* (2013) **15**:52–62. doi:10.1016/j.ymeth.2012.12.012
- Knechel NA. Tuberculosis: pathophysiology, clinical features and diagnosis. *Crit Care Nurse*. 2009;29:34-43.

- Schluger NW, Rom WN. The host immune response to tuberculosis. *Am J Respir Crit Care Med.* 1998;157:679-91.
- Ramamurti T. Pathology of mycobacterial infection in diabetes. *Int J Diab Dev Countries.* 1999;19:56-60
- Van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to mycobacterium tuberculosis. *Clin Microbiol Rev.* 2002;15(2):294-309
- Subagyo A, Aditama TY, Sutoyo DK, Partakusuma LG. Pemeriksaan interferon-gamma dalam darah untuk deteksi infeksi tuberkulosis. *Jurnal Tuberkulosis Indonesia.* 2006;3:6-19.
- Djoerban , Djauzi S. HIV/AIDS di Indonesia. In : Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata MK, Setiati S, eds. *Buku Ajar Ilmu Penyakit Dalam.* 4th ed. Jakarta:Pusat Penerbitan Departemen Ilmu Penyakit Dalam. FKUI 2006.
- Aditama TY, Yuharmen, Subuh H. M. Rencana aksi nasional TB-HIV. Pengendalian tuberkulosis 2011-2014. Kementerian Kesehatan RI. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. 2011:2-5.
- Datiko D. G, Yassin M. A, Chekol LT, Kabeto LE, Lindtjorn B. The rate of TB-HIV co-infection depends on the prevalence of HIV infection in a community. *BMC Public Health.* 2008:2-8.
- Bakari M, Aris M, Chale S, Josiah R, Magao P, Pallangyo N, et al. Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in dar Es Salam. 2000:494-98.
- Departemen Kesehatan Republik Indonesia. Kebijakan Nasional Kolaborasi TB/HIV edisi pertama versi 27 september 2007;10-20.
- Heiner C, Bucher, Lauren E. Griffith,Gordon H,Guyott. Isoniazid Prophylaxis for tuberculosis in HIV infection: a meta-analysis of Randomized controlled trials. *AIDS.* 1999;13:5011-7.
- Departemen Kesehatan Republik Indonesia. Kebijakan Nasional Kolaborasi TB/HIV edisi pertama versi 27 setember 2007. 2007;10-20.




- Heiner C, Bucher, Lauren E. Griffith, Gordon H, Guyott. Isoniazid Prophylaxis for tuberculosis in HIV infection: a meta-analysis of Randomized controlled trials. *AIDS*. 1999;13:5011-7.
- Dye, Scheele S, Dolin P, Pathona V, Raviglione MC. Global Burden of Tuberculosis estimated incidence and mortality by Country. *JAMA*. 1999;282:677-86.
- WHO. TB/HIV a clinical manual. 2nd ed. Geneva:WHO press;2004:1-56.
- Fee MJ, Oo M. M, Gabayan A. E, Rodin D. R, Barnes P. F. Abdominal tuberculosis in patients infected with the HIV. *Clin Infect Dis* 1995;20:938-44.
- WHO. Global tuberculosis programme: Global Tuberculosis control. WHO report;2000.
- Crofton J, Chaulet P, Maher D. Guidelines for management of drug resistant tuberculosis. 2nd ed. Geneva:WHO;1997.
- WHO. TB/HIV a clinical manual. 2nd ed. Geneva:WHO press;2004:1-56.
- Frieden T. T. Tuberculosis case detection, treatment and monitoring, questions and answers. 2nd ed. Geneva:WHO;2004:104-6.
- Iseman MD. Treatment and implications of multidrug-resistant tuberculosis for the 21st century. *Chemotherapy*. 1999;45:34-40.
- WHO. Case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. WHO press;2006:1-38.
- Wormser GP. AIDS and other manifestations of HIV infection. 4th ed. New York:Elsevier;2003:399-440.
- Department of Health and Human Services Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health care settings. *CDC* 2006;55:1-8.

- Wormser GP. AIDS and other manifestations of HIV infection. 4th ed. New York:Elsevier;2003:399-440.
- Cahn P, Perez H, Ben G, Ochoa C. Tuberculosis and HIV : a partnership against the most vulnerable. JIAPAC. 2003;2:106-23.
- Sharma SK, Mohan A, Kadiravan T. HIV-TB co-infection: Epidemiology, diagnosis & management. Indian. Med Res 2005;121:550.
- Gavin J , Louis J. The 3 I's satellite symposium reducingg the risk of Tuberculosis in HIV infected individuals. 4th South African AIDS Conference. 2009.
- Frieden T. T. Tuberculosis case detection,treatment and monitoring,questions and answers. 2nd ed. Geneva:WHO;2004:104-6.
- Aditama TY. Tuberkulosis,diagnosis,terapi dan masalahnya. Edisi V. Jakarta;2005:37-48.
- Departement of Health and Human services Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents and pregnant women in health care settings. CDC 2006;55:1-8.
- Lesley Scott. Point of care of TB testing: Experience with the GeneXpert MTB/RIF. Presented at the 4th INTEREST workshop. 2010.
- Lamprey PR, Johnson L,Khan M. The Global challenge of HIV and AIDS. Population Bulettin 2006;61:1-28.
- World Health Organization. Global Tuberculosis Control: The burden of disease caused by TB. Geneva: WHO Press; 2011. 9-27.
- Prasad CE. Immunodeficiencies in diabetes and mycobacterial infections. Int J Diab Dev Countries. 1999;19:52-5.
- Alisjahbana B, van Crevel B, Sahiratmadja E, den Heijer M, Maya A, Istriana E, et al. Diabetes melitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis. 2006; 6:696-700.

- Guptan A, Shah A. Tuberculosis and diabetes: an appraisal. *Ind J Tub.* 2000;47:2-8.
- Jabbar A, Hussain SF, Khan AA. Clinical characteristics of pulmonary tuberculosis in adult Pakistani patients with co-existing diabetes melitus. *East Med Health J.* 2006;12:522-7.
- Jeon CY, Murray MB. Diabetes melitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. 2008 [cited 2010 May 14] 5:1091-1110. Available from:<http://plosmedicine.org/article/info/doi.1371/journal.pmed.0050152.pdf>.
- Ljubic S, Balachandran A, Pavlic-Renar I, Barada A, Metelko Z. Pulmonary infections in diabetes melitus. *Diabetologia Croatica.* 2004;33(4):56-60.
- Restrepo BI, Fisher-Hoch SP, Pino PA, Salinas A, Rahbar MH, Mora F, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. *Clin Infect Dis.* 2008;47(5):634-41.
- Bacakoglu F, Basoglu OK, Cok G, Sayner A, Ates M. Pulmonary tuberculosis in patients with diabetes mellitus. *Respiration.* 2001;68:595-600.
- Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, Leung GM, et al. Diabetic control and risk of tuberculosis: a cohort study. *Am J Epid.* [serial on the internet]. 2008 [cited 2010 June 30]. Available from: <http://aje.oxfordjournals.org>
- Van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to mycobacterium tuberculosis. *Clin Microbiol Rev.* 2002;15(2):294-309
- Perez-Guzman C, Torres-Cruz A, Villareal-Velarde H, Salazar-Lezama MA, Vargas MH. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. *Int J Tuberc Lung Dis.* 2001;5(5)

- Yurteri G, Sarac S, Dalkulic O, Ofluoglu H, Demiroz F. Features of pulmonary in patients with diabetes melitus: a comparative study. Turkish Resp J. 20
- World Health Organization. Key point. WHO Report 2008 : Global Tuberculosis Control 2008 surveillance, planning, financing. Geneva, Switzerland: WHO;2008. p. 3-7.
- Badan Penelitian dan Pengembangan Kesehatan 2004. Survei Kesehatan Rumah Tangga, 2004. Jakarta: Badan Litbang Depkes 2004
- World Health Organization. Profiles of high-burden countries. Country profile Indonesia. WHO Report 2008 : Global Tuberculosis Control 2008 surveillance, planning, financing. Geneva, Switzerland: WHO; 2008. p. 113-8.
- Aditama T Y. Tuberkulosis Masalah dan Perkembangannya. Pidato Pengukuhan Guru Besar Tetap dalam Bidang Pulmonologi dan Ilmu Kedokteran Respirasi FKUI. Jakarta: UI Press; 2008. p. 22-7.
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneve, Switzerland: WHO; 2006. p. 1-8.
- World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, Switzerland: WHO; 2003. p. 39-47
- Crofton SJ, Chaulet P, Maher D. Guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: WHO, 1996. p. 5-9.
- Francis J. Curry National Tuberculosis Center, San Francisco Departement of Public Health, University of California. Drug – Resistant Tuberculosis a Survival Guide for Clinicians. Loeffler AM, Daley CL, Flood JM editors. California San francisco: CDC, 2004. p. 1-14.

- Munsiff SS, Bassoff T, Nivin B, et al. Molecular epidemiology of multidrug-resistant tuberculosis, New York City, 1995-1997. *Emerg Infect Dis.* 2002;8(11):1230-1238.
- The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. *Anti-Tuberculosis Drug Resistance in the World. Report No. 3.* Geneva: World Health Organization; 2004
- Partners In Health, Harvard Medical School, Bill & Melinda Gates Foundation. *A DOTS-Plus Handbook Guide to the Community based Treatment of MDR TB.* Boston, Massachusetts: PIH,2002. p. 1-13.
- Parsons LM, Somoskovi A, Urbanczik R, Salfinger M. Laboratory diagnostic aspects of drug resistant tuberculosis. *Front Biosci.* 2004; 9:2086-2105
- Sarin R. MDR-TB – Interventional Strategy. *Indian J Tuberc* 2007; 54: 110-6.
- American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America. *Treatment of tuberculosis.* *MMWR.* 2003;52(RR-11):1-77.
- Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. *N Engl J Med.* 2003;348(2):119-128
- Partners In Health, Brigham and Women’s Hospital. *Chronic Care for MDR TB Guidelines for Health Centre or Distric Hospital TB Clinic,* Boston, Massachusetts: PIH, 2008. p. 23-35.
- Mukherjee JS, Rich ML, Socci AR, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. *Lancet.* 2004;363(9407):474-481.
- Pomerantz BJ et al. Pulmonary resection for multi-drug resistant tuberculosis. *Journal of Thoracic and Cardiovascular Surgery.* 2001;121(3):448–453.

- Geerligs WA, Altena R , Lange WCM, Soolingen D, Van Der Werf TS. Multidrugresistant tuberculosis: long-term treatment outcome in the Netherlands. *Int J Tuberc Lung Dis.* 2000;4(8):758-764
- Palliative care: symptom management and end-of-life care. Geneva, World Health Organization, 2004 (WHO/CDS/IMAI/2004. 4).
- Farmer PE, Furin JJ, Shin SS. The clinical management of multidrug-resistant tuberculosis. *Journal of Respiratory Diseases* 2000; 21(1):53-6.
- World Health Organization. Guidelines for establishing dots-plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO; 2000. p. 1-31.
- Baratawidjaya KG, Rengganis I. *Imunologi Dasar*. Ed ke-8. Jakarta: FKUI. 2009. 
- Manivannan S, Narayan R V, Ramanathan VD. Anti Mycobacterium tuberculosis IgG Antibody Mediated Complement Activation by M. tuberculosis. *Journal of Immunology and Immunopathology.* 2006; 8(2). (Online). <http://www.indianjournals.com/ijor.aspx?target=ijor:jii&volume=8&issue=2&article=abs014>. Diakses 15 Februari 2018
- Aditama YT, Soedarsono, Zubaedah T, Wiryokusumo HS, Hilaludin S, Bagus NRI, et al. *Tuberkulosis: Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: PDPI. 2006. 
- Paul W. *Fundamental Immunology*. 5<sup>th</sup> Ed. Philadelphia: Lippincott Williams and Wilkins. 2003; p 965-1020
- Jeong JY, Lee KS. Pulmonary Tuberculosis: Up-to-Date Imaging and Management. *American Journal Of Roentgenology.* 2008;191.
- Dranoff G. Cytokines in Cancer Pathogenesis and Cancer Therapy. *Nature Reviews Cancer.* 2004; 4:11-22. (Online) : <http://www.nature.com/nrc/journal/v4/n1/full/nrc1252.html>. Diakses 15 Februari 2018. 
- Smith I. Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence. *Clinical Microbiology Reviews.* 2003; (16)-



3. (Online). <http://cmr.asm.org/cgi/content/abstract/16/3/463>. Diakses 15 Februari 2018.

- Dranoff G. Cytokines in Cancer Pathogenesis and Cancer Therapy. *Nature Reviews Cancer*. 2004; 4:11-22. (Online) : <http://www.nature.com/nrc/journal/v4/n1/full/nrc1252.html>. Diakses 15 Februari 2018.
- Foo Y. Liew, Damo Xu, Elizabeth K. Brint, Luke A. A. J. O'Neill, 2005. Negative regulation of Toll-Like receptor-mediated immune response. *Nature Review Immunology*: vol. 5:446-458.
- Gay J. Nicholas, Monique Gangloff & Alexander N. R Weber, 2006. Toll-Like receptors as molecular switches. *Nature Reviews Immunology*, September ; 6:693-698.
- Fleer Andre, Tannette G. Krediet, 2007. Innate Immunity: Toll-Like Receptors and Some More. *Neonatology*; vol. 92:145-157
- Lauren E Yauch, Michael K. Mansour, Shmuel Shoham, James B. Rottman, and Stuart M. Levitz, September 2004. Involvement of CD14, Toll-Like Receptors 2 and 4, and MyD88 in the Host Response to the Fungal Pathogen *Cryptococcus neoformans* In vivo. *Infection and Immunity*, vol. 72: NO. 9:5373-5382.
- Crevel V, Tom HM, Ottenhoff, Jos WM. Innate immunity to *Mycobacterium tuberculosis*. *Clinical microbiology review*. 2002. p. 294-309.
- Joost J, Openheim. Cytokines. In: Tristram GP, Daniel PS, Abba IT. *Medical Immunology*. 10<sup>th</sup> ed. California; Elsevier: 2001. p. 95-112.
- Jordao, L. Dan Otilia V. Vieira. 2011. Tuberculosis: new aspects of an old disease. *International Journal of Cell Biology*. Volume 2011.
- Peyron P. , J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Da'é, J. F. Emile, B. Marchou, P. J. Cardona, C. de Chastellier and F. Altare. 2008. Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for *M. Tuberculosis* persistence. *PLoS Pathog*. 4: e1000204.
- PNPK. Pedoman nasional pelayanan kedokteran tata laksana

tuberkulosis. 2019.

- Soelistijo SA, Novida H, Rudijanto A, Soewondo P, Suastika K, Manaf A, et al. Konsensus pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. PERKENI; 2015. 79 p.
- Restrepo B. Diabetes and tuberculosis. *Microbiol Spectr*. 2016;4(6):1–19.
- World Health Organization. Global tuberculosis report 2020. Geneva; 2020.
- Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Kaabi J Al. Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. *J Epidemiol Glob Health*. 2020;10(1):107–11.
- Berbudi A, Rahmadika N, Tjahjadi Al, Ruslami R. Type 2 Diabetes and its Impact on the Immune System. *Curr Diabetes Rev*. 2019;16(5):442–9.
- Alfarisi O, Mave V, Gaikwad S, Sahasrabudhe T, Ramachandran G, Kumar H, et al. Effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment. *Antimicrob Agents Chemother*. 2018;62(11):1–14.
- Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. *Clin Infect Dis*. 2006;43(7):848–54.
- Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, et al. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus. *Antimicrob Agents Chemother*. 2013;57(11):5740–2.
- Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association

between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. *PLoS One*. 2017;12(11):1–26.

- Alves C, Casqueiro J, Casqueiro J. Infections in patients with diabetes mellitus: A review of pathogenesis. *Indian J Endocrinol Metab*. 2012;16(7):27.
- Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. *J Diabetes Res*. 2018;2018:1–9.
- Magee MJ, Salindri AD, Kyaw NTT, Auld SC, Haw JS, Umpierrez GE. Stress Hyperglycemia in Patients with Tuberculosis Disease: Epidemiology and Clinical Implications. *Curr Diabetes Rev*. 2019;18(9):1–18.
- Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clin Infect Dis*. 2007;45(4):428–35.
- Morris JT, Seaworth BJ, McAllister CK. Pulmonary tuberculosis in diabetics. *Chest*. 1992;102(2):539–41.
- Leung CC, Yew WW, Mok TYW, Lau KS, Wong CF, Chau CH, et al. Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis. *Respirology*. 2017;22(6):1225–32.
- Chiang CY, Lee JJ, Chien ST, Enarson DA, Chang YC, Chen YT, et al. Glycemic control and radiographic manifestations of tuberculosis in diabetic patients. *PLoS One*. 2014;9(4):1–9.
- Fonseca AAD, Pinto ACG, Paizao TP da, Alberio CAA, Vieira JLF. Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis? *Brazilian J Infect Dis*. 2020;24(4):352–5.

- Kumar AKH, Chandrasekaran V, Kannan T, Murali AL, Lavanya J, Sudha V, et al. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. *Eur J Clin Pharmacol*. 2017;73(1):65–70.
- Medellín-Garibay SE, Cortez-Espinosa N, Milán-Segovia RC, Magaña-Aquino M, Vargas-Morales JM, González-Amaro R, et al. Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: Association with biochemical and immunological parameters. *Antimicrob Agents Chemother*. 2015;59(12):7707–14.
- Riza LA, Pearson F, Ugarte-Gil C, Alisjahbana B, Vijver S van de, Panduru NM, et al. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. *Lancet Diabetes Endocrinol*. 2014;2(9):740–53.
- Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. *Clin Pharmacol Ther*. 2001;69(6):400–6.
- Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. *Clin Pharmacol Ther*. 2003;74(4):334–40.
- Brake LHM, Yunivita V, Livia R, Soetedjo N, Van Ewijk-Beneken Kolmer E, Koenderink JB, et al. Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients. *Clin Pharmacol Ther*. 2019;105(3):730–7.
- Niazi AK, Kalra S. Diabetes and tuberculosis: a review of the role of optimal glycemic control. *J Diabetes Metab*. 2012;11(28):1–4.
- Rao P V. Persons with type 2 diabetes and co-morbid active tuberculosis should be treated with insulin. *Int J Diabetes Dev Ctries*.

1998;19(1):79–86.

- Boglou P, Steiropoulos P, Papanas N, Bouros D. Hypoglycaemia due to interaction of glimepiride with isoniazid in a patient with type 2 diabetes mellitus. *BMJ Case Rep.* 2013;11(36):1–3.
- Ganguly RJ, Abraham RR, Prasad R, Rao BC. Hyperglycaemia induced by isoniazid preventive therapy. *J Fam Med Prim Care.* 2018;7(4):1123–5.
- Manish G, Keshav G, Syed R, Sukriti K, Abhinav G. Isoniazid induced childhood diabetes: A rare phenomenon. *J Basic Clin Pharm.* 2015;6(2):74.
- Arram, E. O. , Hassan, R. & Saleh, M. 2014. Increased Frequency Of Cd4+ Cd25+ Foxp3+ Circulating Regulatory T Cells (Treg) In Tuberculous Patients. *Egyptian Journal Of Chest Diseases And Tuberculosis*, 63, 167-172.
- Baratawidjaja, K. G. & Rengganis, I. 2009. *Imunologi Dasar Edisi Ke-8. Fakultas Kedokteran Universitas Indonesia, Jakarta. Hal, 27-40.*
- Behar, S. M. 2013. Antigen-Specific Cd8+ T Cells And Protective Immunity To Tuberculosis. *The New Paradigm Of Immunity To Tuberculosis.* Springer.
- Chang, J. T. , Dou, H. Y. , Yen, C. L. , Wu, Y. H. , Huang, R. M. , Lin, H. J. , Su, I. J. & Shieh, C. C. 2011. Effect Of Type 2 Diabetes Mellitus On The Clinical Severity And Treatment Outcome In Patients With Pulmonary Tuberculosis: a Potential Role In The Emergence Of Multidrug-Resistance. *J Formos Med Assoc*, 110, 372-81.
- Commandeur, S. , Lin, M. Y. , Van Meijgaarden, K. E. , Friggen, A. H. , Franken, K. L. M. C. , Drijfhout, J. W. , Korsvold, G. E. , Oftung, F. , Geluk, A. & Ottenhoff, T. H. M. 2011. Double- And Monofunctional Cd4+ And Cd8+ T-Cell Responses To Mycobacterium Tuberculosis

Dosr Antigens And Peptides In Long-Term Latently Infected Individuals. *European Journal Of Immunology*, 41, 2925-2936.

- Crofton, S. J. , Chaulet, P. , Maher, D. , Grosset, J. , Harris, W. , Horne, N. , Iseman, M. & Watt, B. 1997. Guidelines For The Management Of Drug-Resistant Tuberculosis. World Health Organization.
- Day, C. L. , Abrahams, D. A. , Lerumo, L. , Janse Van Rensburg, E. , Stone, L. , O'Rie, T. , Pienaar, B. , De Kock, M. , Kaplan, G. , Mahomed, H. , Dheda, K. & Hanekom, W. A. 2011. Functional Capacity Of <Em>Mycobacterium Tuberculosis</Em>-Specific T Cell Responses In Humans Is Associated With Mycobacterial Load. *The Journal Of Immunology*, 187, 2222.
- Devaraj, S. , Dasu, M. R. , Rockwood, J. , Winter, W. , Griffen, S. C. & Jialal, I. 2008. Increased Toll-Like Receptor (Tlr) 2 And Tlr4 Expression In Monocytes From Patients With Type 1 Diabetes: Further Evidence Of a Proinflammatory State. *The Journal Of Clinical Endocrinology & Metabolism*, 93, 578-583.
- Farsida, Shabariah, R. , Hatta, M. , Patellongi, I. , Prihantono, Nasrum Massi, M. , Asadul Islam, A. , Natzir, R. , Dwi Bahagia Febriani, A. , Hamid, F. , Fatimah, Akaputra, R. & Aprilia Savitri, P. 2021. Relationship Between Expression Mrna Gene Treg, Treg, Cd4+, And Cd8+ Protein Levels With Tst In Tuberculosis Children: A Nested Case-Control. *Annals Of Medicine And Surgery*, 61, 44-47.
- Gay, N. J. , Gangloff, M. & Weber, A. N. 2006. Toll-Like Receptors As Molecular Switches. *Nature Reviews Immunology*, 6, 693-698.
- Jordao, L. & Vieira, O. V. 2011. Tuberculosis: New Aspects Of An Old Disease. *International Journal Of Cell Biology*, 2011.
- Lim, H. J. , Park, J. S. , Cho, Y. J. , Yoon, H. I. , Park, K. U. , Lee, C. T. & Lee, J. H. 2013. Cd4(+)Foxp3(+) T Regulatory Cells In Drug-

Susceptible And Multidrug-Resistant Tuberculosis. *Tuberculosis (Edinb)*, 93, 523-8.

- Liu, Q. , Li, W. , Xue, M. , Chen, Y. , Du, X. , Wang, C. , Han, L. , Tang, Y. , Feng, Y. , Tao, C. & He, J. -Q. 2017. Diabetes Mellitus And The Risk Of Multidrug Resistant Tuberculosis: a Meta-Analysis. *Scientific Reports*, 7, 1090.
- Miya, A. , Nakamura, A. , Miyoshi, H. , Takano, Y. , Sunagoya, K. , Hayasaka, K. , Shimizu, C. , Terauchi, Y. & Atsumi, T. 2018. Impact Of Glucose Loading On Variations In Cd4(+) And Cd8(+) T Cells In Japanese Participants With Or Without Type 2 Diabetes. *Frontiers In Endocrinology*, 9, 81-81.
- Mohammad, M. K. , Morran, M. , Slotterbeck, B. , Leaman, D. W. , Sun, Y. , Grafenstein, H. V. , Hong, S. -C. & Mcinerney, M. F. 2006. Dysregulated Toll-Like Receptor Expression And Signaling In Bone Marrow-Derived Macrophages At The Onset Of Diabetes In The Non-Obese Diabetic Mouse. *International Immunology*, 18, 1101-1113.
- Mollel, E. W. & Chilongola, J. O. 2017. Predictors For Mortality Among Multidrug-Resistant Tuberculosis Patients In Tanzania. *Journal Of Tropical Medicine*, 2017.
- Najmi, N. , Kaur, G. , Sharma, S. K. & Mehra, N. K. 2010. Human Toll-Like Receptor 4 Polymorphisms Tlr4 Asp299Gly And Thr399Ile Influence Susceptibility And Severity Of Pulmonary Tuberculosis In The Asian Indian Population. *Tissue Antigens*, 76, 102-9.
- Nijland, H. M. , Ruslami, R. , Stalenhoef, J. E. , Nelwan, E. J. , Alisjahbana, B. , Nelwan, R. H. , Van Der Ven, A. J. , Danusantoso, H. , Aarnoutse, R. E. & Van Crevel, R. 2006. Exposure To Rifampicin Is Strongly Reduced In Patients With Tuberculosis And Type 2 Diabetes. *Clin Infect Dis*, 43, 848-54.

- Petruccioli, E. , Chiacchio, T. , Pepponi, I. , Vanini, V. , Urso, R. , Cuzzi, G. , Barcellini, L. , Cirillo, D. M. , Palmieri, F. , Ippolito, G. & Goletti, D. 2016. First Characterization Of The Cd4 And Cd8 T-Cell Responses To Quantiferon-Tb Plus. *Journal Of Infection*, 73, 588-597.
- Rozot, V. , Patrizia, A. , Vigano, S. , Mazza-Stalder, J. , Idrizi, E. , Day, C. L. , Perreau, M. , Lazor-Blanchet, C. , Ohmiti, K. , Goletti, D. , Bart, P. -A. , Hanekom, W. , Scriba, T. J. , Nicod, L. , Pantaleo, G. & Harari, A. 2015. Combined Use Of Mycobacterium Tuberculosis–Specific Cd4 And Cd8 T-Cell Responses Is a Powerful Diagnostic Tool Of Active Tuberculosis. *Clinical Infectious Diseases*, 60, 432-437.
- Saktiawati, A. M. I. & Subronto, Y. W. 2018. Influence Of Diabetes Mellitus On The Development Of Multi Drug Resistant-Tuberculosis In Yogyakarta. *Acta Med Indones*, 50, 11-17.
- Schurz, H. , Daya, M. , Möller, M. , Hoal, E. G. & Salie, M. 2015. Tlr1, 2, 4, 6 And 9 Variants Associated With Tuberculosis Susceptibility: A Systematic Review And Meta-Analysis. *Plos One*, 10, e0139711.
- Smith, I. 2003. Mycobacterium Tuberculosis Pathogenesis And Molecular Determinants Of Virulence. *Clinical Microbiology Reviews*, 16, 463-496.
- Soedarsono, S. , Amin, M. , Tokunaga, K. , Yuliwulandari, R. , Dewi, D. N. S. S. & Mertaniasih, N. M. 2020. Association Of Disease Severity With Toll-Like Receptor Polymorphisms In Multidrug-Resistant Tuberculosis Patients. *International Journal Of Mycobacteriology*, 9, 380.
- Song, T. , Li, L. , Liu, J. & Geng, S. 2018. Study On The Relationship Between Changes Of Immune Cells And Tnf- $\alpha$  In Peripheral Blood Of Patients With Multidrug-Resistant And Extensively Drug-Resistant Tuberculosis. *Eur. Rev. Med. Pharmacol*, 22, 1061-1065.



- Wijaya, I. 2015. Tuberkulosis Paru Pada Penderita Diabetes Melitus. *Cermin Dunia Kedokteran*, 42, 412-417.
- Wu, Y. E. , Peng, W. G. , Cai, Y. M. , Zheng, G. Z. , Zheng, G. L. , Lin, J. H. , Zhang, S. W. & Li, K. 2010. Decrease In Cd4+Cd25+Foxp3+ Treg Cells After Pulmonary Resection In The Treatment Of Cavity Multidrug-Resistant Tuberculosis. *International Journal Of Infectious Diseases*, 14, e815-e822.
- Yamamoto, M. , Sato, S. , Hemmi, H. , Hoshino, K. , Kaisho, T. , Sanjo, H. , Takeuchi, O. , Sugiyama, M. , Okabe, M. , Takeda, K. & Akira, S. 2003. Role Of Adaptor Trif In The Myd88-Independent Toll-Like Receptor Signaling Pathway. *Science*, 301, 640-3.